Last updated: 11/07/2018 00:47:30
An Open-Label, Multicenter Study of Single Agent Oral Topotecan Daily Times Five Every 21 Days For First-Line Treatment in Patients with Extensive SCLC Eligible for Oral Therapy
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An Open-Label, Multicenter Study of Single Agent Oral Topotecan Daily Times Five Every 21 Days For First-Line Treatment in Patients with Extensive SCLC Eligible for Oral Therapy
Trial description: An Open-Label, Multicenter Study of Single Agent Oral Topotecan Daily Times Five Every 21 Days For First-Line Treatment in Patients with Extensive SCLC Eligible for Oral Therapy
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Eckardt J, Palmer MC, Fanucchi M, Gralla R, Martins H, Poulin R, Fields SZ. 2000. Oral Topotecan (OT) as Single-Agent First-Line Treatment for Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Ineligible for Standard IV Therapy: A phase II study. Proc. ASCO 19, 494a, (abstract 1932).
Eckardt JR, Palmer MC, Fanucchi MP, Gralla R, Martins H, Poulin R, Fields SZ. 2000. Single Agent Oral Topotecan (OT) as First-Line Treatment for Patients (pts) with Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Ineligible for Standard Therapy: A Phase II Study. Lung Cancer 29, 10, (abstract 25).
Eckardt JR, Palmer MC, Fanucchi MP, Martins H, Gralla R, Poulin R, Fields SZ. 1999. Oral Topotecan (T) as Single-Agent First-Line Treatment for Patients (pts) with Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Ineligible for Standard IV Therapy: A Phase II Study. Proc. ASCO 18, 501a, (abstract 1935).
Medical condition
Lung Cancer, Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
December 1996 to November 2000
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-10-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website